Market-Driven Free Access to Journal Articles

Authors of journal articles want their efforts certified by peer review and made conveniently available to the widest possible readership. They do not expect royalties nor do they receive them. What they hope for is impact. More specifically, they hope for attention, especially from other researchers, and recognition, especially from those who decide which researchers should be hired or promoted. Journal articles have greater impact if they are immediately and widely accessible. In this Internet

Written byThomas Walker
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Publishers of journals, whether societies or commercial publishers, wish to meet expenses and make a profit. Commercial publishers strive to maximize profits, which has led them to increases in journal prices at rates far in excess of inflation. This, in turn, has led to the "serials crisis" in which research libraries must cancel subscriptions that their clients consider essential. Reduced subscriptions have led to still higher journal prices (to maintain profits), further aggravating the crisis.

Journal publishers are taking advantage of the Web's quick, convenient delivery of information by creating electronic versions of their traditional, print journals. To protect their subscription revenues, they have made the e-versions accessible only to those who have paid for a subscription or who are clients of a library that has paid for a site license to the journal. Authors who want their refereed work to be accessible toll-free on the Web concurrent with paper ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies